Onterris (ONT) Earnings Date & Reports

Key Takeaways

• Revenue rose 12.3% at constant currency (CC) to £116.7 million, but came in below management's earlier expectations as China and the Middle East weighed on performance.
• Gross margin expanded by 400 basis points (bps) to 62.2%, while the adjusted EBITDA loss narrowed sharply to £22.1 million from £48.3 million a year earlier.
• Growth was strongest in applied markets, with Clinical revenue up 35.4% and BioPharma up 25.0%, while Research grew a more modest 5.4%.
• The company reaffirmed its target of adjusted EBITDA breakeven in FY27 and positive free cash flow in FY28.
• Full-year 2026 guidance was maintained at 16–20% constant-currency revenue growth, excluding a $20 million non-recurring licensing fee.
• For more detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the related pages.
• Discover Trending AI Robots to explore AI-driven trading strategies and market ideas.

Earnings Context and Why It Matters

Oxford Nanopore's interim results matter because they test whether the company can keep growing while closing the gap to profitability. For the six months ended 30 June 2026, the narrative shifted from pure revenue momentum to operating leverage, with gross margin up 400 bps and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) losses more than halving. Investors are watching closely because the company is still loss-making and has pledged to reach adjusted EBITDA breakeven in FY27 and positive free cash flow in FY28. Regional headwinds, particularly a roughly 16% decline in China revenue, added a layer of caution to an otherwise improving cost and margin story.

Reported Results

Revenue for the first half reached £116.7 million, up 12.3% at constant currency and 10.5% on a reported basis, but below management's earlier expectations. Growth was led by EMEAI (Europe, Middle East, Africa, and India), up 23.8% at constant currency, and the Americas (AMR), up 12.5%. Asia-Pacific (APAC) declined 8.4%, driven by a 15.7% fall in China linked to enhanced export-control restrictions and changes to commercial operations.

Gross margin rose 400 bps to 62.2%, while adjusted operating costs fell 6.9% year over year. As a result, the adjusted EBITDA loss narrowed to £22.1 million from £48.3 million, and the loss for the period fell to £48.0 million from £71.8 million. By end market, Clinical revenue grew 35.4%, BioPharma 25.0%, Industrial 6.2%, and Research 5.4%. Cash and liquid investments stood at £234.5 million at 30 June 2026, down from £302.8 million at the end of 2025, partly reflecting a seasonal working-capital outflow.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Oxford Nanopore, it can be a useful way to surface comparable opportunities and monitor shifting technical conditions across the sector.

Market Reaction and Investor Sentiment

Shares rose sharply on results day, with media reports indicating a gain of roughly 16% as investors focused on the margin improvement and narrowing losses rather than the softer top-line result. The market appeared to reward evidence that restructuring and efficiency measures are translating into operating leverage. Sentiment heading into the report had been cautious given the China and Middle East headwinds, but the combination of a 400 bps gross-margin gain, a halving of the adjusted EBITDA loss, and reaffirmed profitability targets helped reassure investors about the company's path to breakeven.

Forward Outlook and Key Factors to Monitor

Management maintained its 2026 guidance, targeting constant-currency revenue growth of 16–20% excluding a $20 million non-recurring licensing fee from a newly announced cross-licensing agreement with a global diagnostics company. Including that fee, growth is expected to reach roughly 23–27%. The company also expects gross margin of approximately 62%, or about 64% including the licensing income, and now guides adjusted operating costs to decline 2% to remain flat, an improvement from the prior range of 0–5% growth.

Investors should monitor whether revenue reaccelerates in the second half as new device placements convert into consumable demand and as comparisons ease against ended research programs. The second-half recognition of the $20 million licensing fee at 100% gross margin should provide a one-off boost, but the longer-term royalty stream tied to the agreement remains the more meaningful driver and is not included in guidance.

Beyond 2026, the company reaffirmed adjusted EBITDA breakeven in FY27 and positive free cash flow in FY28, alongside a new target of more than $700 million in revenue by 2030 with an adjusted EBITDA margin above 15%. Key factors to watch include the pace of recovery in China, execution on clinical and biopharma adoption, gross-margin durability, and continued cost discipline as the business scales toward profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations